-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] The amount of R&D investment is an important indicator of the innovation of pharmaceutical companies.
From the perspective of pharmaceutical companies that have disclosed R&D investment data, local pharmaceutical companies are accelerating the pace of innovation and transformation
.
In 2021, a large number of pharmaceutical companies will invest in R&D to record highs.
Among the 59 listed companies in the A-share + H-share pharmaceutical and biological industry (Shenwan industry classification) with a revenue of over 10 billion, at least 37 pharmaceutical companies have invested more than 100 million in R&D.
9 pharmaceutical companies invested more than 1 billion yuan in research and development
.
The R&D investment of Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC and other companies has exceeded 3 billion yuan on average, reaching 6.
203 billion yuan, 4.
975 billion yuan, 3.
82 billion yuan, and 3.
433 billion yuan respectively
.
From the perspective of the proportion of R&D investment in operating income, among these 59 companies, Hengrui Medicine takes the lead with a proportion of 23.
95%
.
In addition, there are about 10 pharmaceutical companies whose R&D investment accounts for more than 10% of their operating income
.
Judging from the year-on-year growth of R&D investment, the R&D investment of nearly 50 pharmaceutical companies has achieved year-on-year growth, including Hengrui Medicine, Fosun Pharma, Mindray Medical and other companies whose R&D investment has reached a record high
.
High R&D investment has brought fruitful results to many pharmaceutical companies.
For example, after years of development, Hengrui Medicine has formed a large-scale, professional and comprehensive global R&D team of more than 5,400 people.
R&D centers have been set up in Shanghai, Chengdu, the United States, and Europe; under the high-intensity R&D investment, fruitful results have been achieved.
At present, Hengrui Medicine has listed 10 innovative drugs, and more than 60 innovative drugs are under clinical development, 250 A number of clinical trials have been carried out at home and abroad
.
Another example is Fosun Pharma.
As of the end of 2021, Fosun Pharma has 64 innovative drugs under development
.
Among them, there are 27 self-developed small molecule innovative drugs, 26 self-developed biological innovative drugs, 14 licensed and imported innovative drugs, and 14 self-developed biosimilar drugs
.
The industry believes that from the perspective of the R&D investment of these leading pharmaceutical companies, the pace of innovation and transformation of local pharmaceutical companies is accelerating, and continuous R&D investment will help pharmaceutical companies to bring competitive advantages in products and technologies, and also help The business performance of the company continued to grow steadily
.
It is worth mentioning that pharmaceutical innovation is not easy.
It has the characteristics of long investment cycle and high risk, which is very challenging for pharmaceutical companies
.
In recent years, although the development of the domestic innovative drug industry is in full swing, many pharmaceutical companies are clustering on PD-1 and other highly deterministic targets
.
At the same time, the "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented by Clinical Value" issued by CDE also supports the research and development of "true primary innovation" and scarce First-in-class products.
"Pseudo-innovation" signal, the pressure on pharmaceutical innovation enterprises will be even greater in the future
.
In this regard, the industry said that the current pharmaceutical industry is still in the throes of transformation.
With the improvement of the threshold for innovation and R&D, pharmaceutical companies with truly innovative capabilities and differentiated R&D pipelines are expected to usher in opportunities
.
In addition, in the case of increasingly fierce domestic competition, more and more pharmaceutical companies are turning to overseas markets
.
He believes that "going out" to participate in international competition is a trend and a new way out for local pharmaceutical companies
.
However, it is also not easy for pharmaceutical companies to go overseas.
They also need to face the challenges of differentiated positioning of overseas products, overseas clinical trials, foreign drug application approval, overseas business management, overseas policy and legal risks, etc.
, and they need to be fully prepared.
and courage to face challenges
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
From the perspective of pharmaceutical companies that have disclosed R&D investment data, local pharmaceutical companies are accelerating the pace of innovation and transformation
.
In 2021, a large number of pharmaceutical companies will invest in R&D to record highs.
Among the 59 listed companies in the A-share + H-share pharmaceutical and biological industry (Shenwan industry classification) with a revenue of over 10 billion, at least 37 pharmaceutical companies have invested more than 100 million in R&D.
9 pharmaceutical companies invested more than 1 billion yuan in research and development
.
The R&D investment of Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC and other companies has exceeded 3 billion yuan on average, reaching 6.
203 billion yuan, 4.
975 billion yuan, 3.
82 billion yuan, and 3.
433 billion yuan respectively
.
From the perspective of the proportion of R&D investment in operating income, among these 59 companies, Hengrui Medicine takes the lead with a proportion of 23.
95%
.
In addition, there are about 10 pharmaceutical companies whose R&D investment accounts for more than 10% of their operating income
.
Judging from the year-on-year growth of R&D investment, the R&D investment of nearly 50 pharmaceutical companies has achieved year-on-year growth, including Hengrui Medicine, Fosun Pharma, Mindray Medical and other companies whose R&D investment has reached a record high
.
High R&D investment has brought fruitful results to many pharmaceutical companies.
For example, after years of development, Hengrui Medicine has formed a large-scale, professional and comprehensive global R&D team of more than 5,400 people.
R&D centers have been set up in Shanghai, Chengdu, the United States, and Europe; under the high-intensity R&D investment, fruitful results have been achieved.
At present, Hengrui Medicine has listed 10 innovative drugs, and more than 60 innovative drugs are under clinical development, 250 A number of clinical trials have been carried out at home and abroad
.
Another example is Fosun Pharma.
As of the end of 2021, Fosun Pharma has 64 innovative drugs under development
.
Among them, there are 27 self-developed small molecule innovative drugs, 26 self-developed biological innovative drugs, 14 licensed and imported innovative drugs, and 14 self-developed biosimilar drugs
.
The industry believes that from the perspective of the R&D investment of these leading pharmaceutical companies, the pace of innovation and transformation of local pharmaceutical companies is accelerating, and continuous R&D investment will help pharmaceutical companies to bring competitive advantages in products and technologies, and also help The business performance of the company continued to grow steadily
.
It is worth mentioning that pharmaceutical innovation is not easy.
It has the characteristics of long investment cycle and high risk, which is very challenging for pharmaceutical companies
.
In recent years, although the development of the domestic innovative drug industry is in full swing, many pharmaceutical companies are clustering on PD-1 and other highly deterministic targets
.
At the same time, the "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented by Clinical Value" issued by CDE also supports the research and development of "true primary innovation" and scarce First-in-class products.
"Pseudo-innovation" signal, the pressure on pharmaceutical innovation enterprises will be even greater in the future
.
In this regard, the industry said that the current pharmaceutical industry is still in the throes of transformation.
With the improvement of the threshold for innovation and R&D, pharmaceutical companies with truly innovative capabilities and differentiated R&D pipelines are expected to usher in opportunities
.
In addition, in the case of increasingly fierce domestic competition, more and more pharmaceutical companies are turning to overseas markets
.
He believes that "going out" to participate in international competition is a trend and a new way out for local pharmaceutical companies
.
However, it is also not easy for pharmaceutical companies to go overseas.
They also need to face the challenges of differentiated positioning of overseas products, overseas clinical trials, foreign drug application approval, overseas business management, overseas policy and legal risks, etc.
, and they need to be fully prepared.
and courage to face challenges
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
